Substance / Medication

Asunaprevir

SNOMED 715390003 UMLS C3491974

Overview

Active Ingredient

asunaprevir

RxNorm CUI

1652103

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

Cirrhosis of liver

Chronic type C viral hepatitis

Administration & Protocol

Dosing, route, and treatment protocol

Administration details including route, dosing schedules, preparation instructions, and contraindications are pending physician authorship.

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

No monitoring biomarkers have been mapped yet. Biomarker-intervention linkages are derived through related conditions and will expand as the knowledge graph grows.

Clinical Trials

102 trials linked to this intervention

102

Total Trials

Recruiting

With Results

Recent Trials

Long-Term Therapy With Ribavirin for Chronic Hepatitis C

NCT00001854Phase 4Completed50 enrolled

Pegylated Interferon and Ribavirin to Treat Chronic Hepatitis C With and Without Kidney Disease

NCT00028093Phase 4Completed50 enrolled

ACCELERATE Study - A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) in Combination With COPEGUS (Ribavirin) in Interferon-Naive Patients With Chronic Hepatitis C (CHC) Infection.

NCT00077636Phase 4Completed1469 enrolled

A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) in Combination With COPEGUS (Ribavirin) in Interferon-Naive Patients With Chronic Hepatitis C Infection (CHC).

NCT00077649Phase 4Completed188 enrolled

A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) in Combination With Ribavirin in Patients With Chronic Hepatitis C (CHC) Previously Treated With PEG-Intron + Ribavirin

NCT00087568Phase 4Completed57 enrolled

View all 102 trials on ClinicalTrials.gov

Research Evidence

Published studies and systematic reviews

Sort:

Beclabuvir in combination with asunaprevir and daclatasvir for hepatitis C virus genotype 1 infection: A systematic review and meta-analysis.

Ahmed Ali Mahmoud, Doheim Mohamed Fahmy, Mattar Omar Mohamed et al. · J Med Virol · 2018

PMID: 28892235Meta-Analysis

Effectiveness and safety of daclatasvir plus asunaprevir for hepatitis C virus genotype 1b: Systematic review and meta-analysis.

Wang Hui-Lian, Lu Xi, Yang Xudong et al. · J Gastroenterol Hepatol · 2017

PMID: 27597318Meta-Analysis

Safety and efficacy of dual direct-acting antiviral therapy (daclatasvir and asunaprevir) for chronic hepatitis C virus genotype 1 infection in patients on hemodialysis.

Toyoda Hidenori, Kumada Takashi, Tada Toshifumi et al. · J Gastroenterol · 2016

PMID: 26872889RCT

Single- and multiple-ascending-dose studies of the NS3 protease inhibitor asunaprevir in subjects with or without chronic hepatitis C.

Pasquinelli Claudio, McPhee Fiona, Eley Timothy et al. · Antimicrob Agents Chemother · 2012

PMID: 22290978RCTFull text (PMC)

Efficacy and safety of 12 weeks of daclatasvir, asunaprevir plus ribavirin for HCV genotype-1b infection without NS5A resistance-associated substitutions.

Yu Ming-Lung, Hung Chao-Hung, Huang Yi-Hsiang et al. · J Formos Med Assoc · 2019

PMID: 30527566Trial

Efficacy and Safety of Daclatasvir and Asunaprevir in Patients with Hepatitis C Virus Genotype 1b Infection on Hemodialysis.

Lee Byung Seok, Song Myeong Jun, Kwon Jung Hyun et al. · Gut Liver · 2019

PMID: 30400729TrialFull text (PMC)

Exposure-Response Analysis for Efficacy of Daclatasvir, Asunaprevir, and Beclabuvir Combinations in HCV-Infected Patients.

Ueno T, Osawa M, Shiozaki T et al. · Clin Pharmacol Drug Dev · 2019

PMID: 30667592Trial

Effects of a Fixed-Dose Co-Formulation of Daclatasvir, Asunaprevir, and Beclabuvir on the Pharmacokinetics of a Cocktail of Cytochrome P450 and Drug Transporter Substrates in Healthy Subjects.

Garimella Tushar, Tao Xiaolu, Sims Karen et al. · Drugs R D · 2018

PMID: 29255971TrialFull text (PMC)

Exposure-Response (Efficacy) Analysis of Daclatasvir and Asunaprevir in Japanese Patients With Hepatitis C Virus Infection.

Ueno Takayo, Osawa Mayu, Imai Yasuhiko et al. · J Clin Pharmacol · 2018

PMID: 30063245TrialFull text (PMC)

Daclatasvir plus asunaprevir in treatment-naïve patients with hepatitis C virus genotype 1b infection.

Wei Lai, Wang Fu-Sheng, Zhang Ming-Xiang et al. · World J Gastroenterol · 2018

PMID: 29599611TrialFull text (PMC)

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Risk profile, common and serious adverse effects, contraindications, and drug interactions are pending physician authorship.

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Quick Facts

Type: Substance / Medication
Fully Specified Name: Asunaprevir (substance)
SNOMED CT: 715390003
UMLS CUI: C3491974
RxNorm CUI: 1652103

Clinical Data

This intervention maps to 2 entities in the Ltrl knowledge graph.

Conditions

Biomarkers

Specialists

Symptoms

102

Clinical Trials

Data is sourced from SNOMED CT, UMLS, and the Ltrl clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.